• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Trends in Microbiology >Taking toll: lipid Amimetics as adjuvants and immunomoduators
【24h】

Taking toll: lipid Amimetics as adjuvants and immunomoduators

机译：付出代价：脂类动物药作为佐剂和免疫调节剂

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Vaccine adjuvants based on the structure of lipid A, such as monophosphoryl lipid A (MLA), have proven to be safe and effective in inducing immune responses to heterologous proteins in animal and human vaccines. Recent work on the development of a recombinant vaccine for leishmaniasis has demonstrated that a clinical grade MLA formulation-MPL adjuvant-is essential in the development of a protective response. Preliminary evidence suggests that MLA and a chemically distinct family of lipid A mimetics-the aminoalkyl glucosaminide 4-phosphates-act on Toll-like receptor 4 (TLR4). As TLR4 agonists, they have potent immunomodulatory effects when used both as vaccine adjuvants and as stand-alone products. Novel approaches to vaccine development could benefit from taking full advantage of the effects of these compounds on innate and adaptive responses.
机译：已经证明，基于脂质A结构的疫苗佐剂（例如单磷酰基脂质A（MLA））可以安全有效地诱导动物和人类疫苗中对异源蛋白质的免疫应答。关于开发用于利什曼病的重组疫苗的最新工作表明，临床级MLA制剂-MPL佐剂-在保护反应的发展中至关重要。初步证据表明，MLA和化学上独特的脂质A模拟物家族-氨基烷基氨基葡萄糖苷4-磷酸酯-作用于Toll样受体4（TLR4）。作为TLR4激动剂，当用作疫苗佐剂和独立产品时，它们具有有效的免疫调节作用。充分利用这些化合物对先天和适应性反应的影响，可以开发出新颖的疫苗开发方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号